Dr. Meghan Shea, MD
Claim this profileBeth Israel Deaconess Medical Center
Area of expertise
Ovarian Cancer
Meghan Shea, MD has run 2 trials for Ovarian Cancer. Some of their research focus areas include:
Endometrial Cancer
Meghan Shea, MD has run 2 trials for Endometrial Cancer. Some of their research focus areas include:
Affiliated Hospitals
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center (BIDMC)
Clinical Trials Meghan Shea, MD is currently running
Letrozole + Abemaciclib vs Pembrolizumab
for Endometrial Cancer
A standard treatment for endometrial cancer is chemotherapy and pembrolizumab together followed by pembrolizumab maintenance for two years. This treatment regimen has shown benefit in terms of delaying cancer progression in prior clinical trials, but the benefit of the pembrolizumab maintenance treatment and whether all participants need it is unclear. This research is being done on the maintenance portion of treatment to compare the efficacy between the combination of letrozole + abemaciclib and pembrolizumab alone following chemotherapy and pembrolizumab. The names of the study drugs involved in this study are: * Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) * Letrozole (a type of aromatase inhibitor) * Pembrolizumab (a type of monoclonal antibody)
Recruiting
1 award
Phase 2
Abemaciclib + Letrozole +/- Metformin
for Endometrial Cancer
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (also known as Glucophage®) * Zotatifin (also known as eFT226) * Gedatolisib (also known as PF-05212384)
Recruiting
1 award
Phase 2
More about Meghan Shea, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Meghan Shea, MD has experience with
- Abemaciclib
- Letrozole
- Cobolimab
- Dostarlimab
- Bevacizumab
- Nivolumab
Breakdown of trials Meghan Shea, MD has run
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Fallopian Tube Cancer
Peritoneal Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Meghan Shea, MD specialize in?
Meghan Shea, MD focuses on Ovarian Cancer and Endometrial Cancer. In particular, much of their work with Ovarian Cancer has involved BRCA negative patients, or patients who are Stage I.
Is Meghan Shea, MD currently recruiting for clinical trials?
Yes, Meghan Shea, MD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Meghan Shea, MD has studied deeply?
Yes, Meghan Shea, MD has studied treatments such as Abemaciclib, Letrozole, Cobolimab.
What is the best way to schedule an appointment with Meghan Shea, MD?
Apply for one of the trials that Meghan Shea, MD is conducting.
What is the office address of Meghan Shea, MD?
The office of Meghan Shea, MD is located at: Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States. This is the address for their practice at the Beth Israel Deaconess Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.